ReShape Lifesciences Inc (RSLS) News

Form 3 - Initial statement of beneficial ownership of securities

Form PRE 14A - Other preliminary proxy statements

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives

IRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier...

ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX

FLEX Technology Designed to Improve the Patient Experience Company Initiating U.S. Product Launch IRVINE...

Form 8-K - Current report

ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds

IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences, Inc. (Nasdaq: RSLS), the premier...

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan

Third Quarter Core Operating Expenses Reduced 37% Compared to Third Quarter of 2022 Cost Reduction Plan To...

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier...

Form 8-K - Current report

Form 8-K - Current report

Form 424B4 - Prospectus [Rule 424(b)(4)]

ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering

IRVINE, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI

IRVINE, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier...